FDA approves new Actos bladder cancer warning
August 4, 2011

The Food and Drug Administration has approved a new warning about the link between the diabetes drug Actos and bladder cancer. The agency called for the new warning after a study found that patients who use Actos for at least one year are 40% more likely to develop bladder cancer.

The FDA's new Actos warning advises doctors not to prescribe the drug to patients with bladder cancer and to use caution in prescribing it to those with a history of the disease. Patients were advised to contact their doctor if they experience signs of blood in their urine, greater urgency in needing to go to the bathroom, back pain or abdominal pain while taking Actos.

Although the FDA has not announced plans to issue an Actos recall, health officials in France and Germany have already stopped sales of the drug in those countries. A study published in France found that Actos was more likely to cause bladder cancer than other diabetes medications.